Cargando…

High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance

BACKGROUND: Active surveillance (AS) is increasingly offered to patients with low risk prostate cancer. The present study was conducted to evaluate the risk of tumor under-grading and -staging for AS eligibility. Moreover, we analyzed possible biomarkers for predicting more unfavorable final tumor h...

Descripción completa

Detalles Bibliográficos
Autores principales: Heidegger, Isabel, Skradski, Viktor, Steiner, Eberhard, Klocker, Helmut, Pichler, Renate, Pircher, Andreas, Horninger, Wolfgang, Bektic, Jasmin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319730/
https://www.ncbi.nlm.nih.gov/pubmed/25658878
http://dx.doi.org/10.1371/journal.pone.0115537
_version_ 1782355995778875392
author Heidegger, Isabel
Skradski, Viktor
Steiner, Eberhard
Klocker, Helmut
Pichler, Renate
Pircher, Andreas
Horninger, Wolfgang
Bektic, Jasmin
author_facet Heidegger, Isabel
Skradski, Viktor
Steiner, Eberhard
Klocker, Helmut
Pichler, Renate
Pircher, Andreas
Horninger, Wolfgang
Bektic, Jasmin
author_sort Heidegger, Isabel
collection PubMed
description BACKGROUND: Active surveillance (AS) is increasingly offered to patients with low risk prostate cancer. The present study was conducted to evaluate the risk of tumor under-grading and -staging for AS eligibility. Moreover, we analyzed possible biomarkers for predicting more unfavorable final tumor histology. METHODS: 197 patients who underwent radical prostatectomy (RPE) but would have met the EAU (European Association of Urology) criteria for AS (PSA<10 ng/ml, biopsy GS ≤6, ≤2 cancer-positive biopsy cores with ≤50% of tumor in any core and clinical stage ≤T2a) were included in the study. These AS inclusion parameters were correlated to the final histology of the RPE specimens. The impact of preoperative PSA level (low PSA ≤4 ng/ml vs. intermediate PSA of >4–10 ng/ml), PSA density (<15 vs. ≥ 15 ng/ml) and the number of positive biopsy cores (1 vs. 2 positive cores) on predicting upgrading and final adverse histology of the RPE specimens was analyzed in uni- and multivariate analyses. Moreover, clinical courses of undergraded patients were assessed. RESULTS: In our patient cohort 41.1% were found under-graded in the biopsy (final histology 40.1% GS7, 1% GS8). Preoperative PSA levels, PSA density or the number of positive cores were not predictive for worse final pathological findings including GS >6, extraprostatic extension and positive resection margin (R1) or correlated significantly with up-grading and/or extraprostatic extension in a multivariate model. Only R1 resections were predictable by combining intermediate PSA levels with two positive biopsy cores (p = 0.004). Sub-analyses showed that the number of biopsy cores (10 vs. 15 biopsy cores) had no influence on above mentioned results on predicting biopsy undergrading. Clinical courses of patients showed that 19.9% of patients had a biochemical relapse after RPE, among all of them were undergraded in the initial biopsy. CONCLUSION: In summary, this study shows that a multitude of patients fulfilling the criteria for AS are under-diagnosed. The use of preoperative PSA levels, PSA density and the number of positive cores were not predictable for undergrading in the present patient collective.
format Online
Article
Text
id pubmed-4319730
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-43197302015-02-18 High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance Heidegger, Isabel Skradski, Viktor Steiner, Eberhard Klocker, Helmut Pichler, Renate Pircher, Andreas Horninger, Wolfgang Bektic, Jasmin PLoS One Research Article BACKGROUND: Active surveillance (AS) is increasingly offered to patients with low risk prostate cancer. The present study was conducted to evaluate the risk of tumor under-grading and -staging for AS eligibility. Moreover, we analyzed possible biomarkers for predicting more unfavorable final tumor histology. METHODS: 197 patients who underwent radical prostatectomy (RPE) but would have met the EAU (European Association of Urology) criteria for AS (PSA<10 ng/ml, biopsy GS ≤6, ≤2 cancer-positive biopsy cores with ≤50% of tumor in any core and clinical stage ≤T2a) were included in the study. These AS inclusion parameters were correlated to the final histology of the RPE specimens. The impact of preoperative PSA level (low PSA ≤4 ng/ml vs. intermediate PSA of >4–10 ng/ml), PSA density (<15 vs. ≥ 15 ng/ml) and the number of positive biopsy cores (1 vs. 2 positive cores) on predicting upgrading and final adverse histology of the RPE specimens was analyzed in uni- and multivariate analyses. Moreover, clinical courses of undergraded patients were assessed. RESULTS: In our patient cohort 41.1% were found under-graded in the biopsy (final histology 40.1% GS7, 1% GS8). Preoperative PSA levels, PSA density or the number of positive cores were not predictive for worse final pathological findings including GS >6, extraprostatic extension and positive resection margin (R1) or correlated significantly with up-grading and/or extraprostatic extension in a multivariate model. Only R1 resections were predictable by combining intermediate PSA levels with two positive biopsy cores (p = 0.004). Sub-analyses showed that the number of biopsy cores (10 vs. 15 biopsy cores) had no influence on above mentioned results on predicting biopsy undergrading. Clinical courses of patients showed that 19.9% of patients had a biochemical relapse after RPE, among all of them were undergraded in the initial biopsy. CONCLUSION: In summary, this study shows that a multitude of patients fulfilling the criteria for AS are under-diagnosed. The use of preoperative PSA levels, PSA density and the number of positive cores were not predictable for undergrading in the present patient collective. Public Library of Science 2015-02-06 /pmc/articles/PMC4319730/ /pubmed/25658878 http://dx.doi.org/10.1371/journal.pone.0115537 Text en © 2015 Heidegger et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Heidegger, Isabel
Skradski, Viktor
Steiner, Eberhard
Klocker, Helmut
Pichler, Renate
Pircher, Andreas
Horninger, Wolfgang
Bektic, Jasmin
High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
title High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
title_full High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
title_fullStr High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
title_full_unstemmed High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
title_short High Risk of Under-Grading and -Staging in Prostate Cancer Patients Eligible for Active Surveillance
title_sort high risk of under-grading and -staging in prostate cancer patients eligible for active surveillance
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4319730/
https://www.ncbi.nlm.nih.gov/pubmed/25658878
http://dx.doi.org/10.1371/journal.pone.0115537
work_keys_str_mv AT heideggerisabel highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT skradskiviktor highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT steinereberhard highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT klockerhelmut highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT pichlerrenate highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT pircherandreas highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT horningerwolfgang highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance
AT bekticjasmin highriskofundergradingandstaginginprostatecancerpatientseligibleforactivesurveillance